This round is no longer accepting investments, but others just like it are live now.

CLOSED

GET A PIECE OF LITON RX

Digital solution to your prescription

We believe our healthcare and pharmacy model is broken. Join in our mission to make healthcare and pharmacy affordable and convenient. At LitonRx, we believe in solving this by focusing on the 3 C's of Care, Convenience and Cost through digital enablement. LitonRx offers an affordable digital pharmacy and subscription based concierge virtual care services. Our product, LitonMD, is currently in development and will be coming soon to the market.

Show more

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Company Image

$126,161 Raised

TEAM

Kishlay Anand

Kishlay Anand • CEO & President

Experienced and Visionary Healthcare leader with passion for Innovation. 

Founder and President of Apricus Health, an innovative tech enabled value based services organization which aligns 3 P’s in Healthcare; Physicians, Payors and Patients.

Founder and CEO 

AKOS, www.AkosMD.com, is an innovative value based integrated care delivery platform with significant ROI for Employers with decreased medical costs, early return to work, lower premiums and timely care for their employees.

Currently, Mr Anand spent approximately 80% of his time focusing on the company and 20% of his time focusing on his other businesses. Please refer to our risk factors and the Directors & Officers section of our offering materials for further details.

Read More

Pankaj Jain

Pankaj Jain • Co-Founder, Treasurer, Director, Advisor (Part-Time)

Dr. Pankaj Jain MD, F.A.A.P, F.A.C.C, is a compassionate physician, visionary entrepreneur and philanthropist. He is a double board-certified Pediatrician and Pediatric Cardiologist.

Dr. Jain has an extensive experience in medical field working in multiple countries (India, U.A.E., Canada and US) for over 20 years, which makes him a distinguished physician. Dr. Jain is an emerging entrepreneur, and gained valuable experience in business by investing in multiple small businesses and startups. Additionally, he provides advice in his family’s overseas business operations, now in its third generation of business. Dr. Jain is humanitarian, committed to uplifting society. He also participates in multiple charity health camps to provide awareness and medical care to unprivileged society.

Read More

Ravi Juvvala

Ravi Juvvala • Chief Technology Officer (Part-Time)

Ravi is a technology architect who builds and manages enterprise solutions. He is a business-focused technology leader with a successful history of leveraging technology to drive innovation and growth. From startups to the most established global companies, he is experienced at driving and managing change while generating improvements in top line revenue, operational efficiencies and competitive advantage. Ravi brings 20+ years of expertise leading and architecting cloud solutions, AI, data analytics, and machine learning for various Fortune 500 clients.

Read More

Reasons to Invest

  • In our view, the current delivery and pharmacy model is broken, and we believe that healthcare needs to be affordable and convenient. 


  • We’ve designed contemporary digital health and prescription services that address key issues including price transparency, convenience and affordability. We provide concierge Physician and Medications on a low monthly subscription model.


  • Healthcare is approximately 20% of US GDP (source). The pharmaceuticals market is estimated to grow from $336 Billion to potentially $505 Billion by 2023 across developed markets (source). We see this as a hot space and consumers are adopting digital health services much faster post COVID.





OVERVIEW


Redefining the pharmacy experience

g

We’re in a new era in digital health, and to us, that means filling prescriptions shouldn’t be a hassle. At LitonRx, we provide a fast, affordable, digital alternative to waiting in line at the pharmacy. Through our subscription-based virtual concierge care and pharmacy fulfillment services, we offer free same-day delivery of covered formulary prescription medications. With Providers and Pharmacists just a click away, we help save time and money for those seeking care. LitonMD, is a product sub-brand of LitonRX. LitonMD is currently in development and expected to launch to the market soon.



We consider ourselves a digital health and pharmacy with a heartbeat. Our mission is to provide price transparency, improve medication access and adherence, and empower our community for better healthcare. With this, we thrive on our connection with providers, pharmacists and patients, and unlike competition, we aim to put patients at the center of our approach.

The Problem & our Solution


We believe to be disrupting a fragmented Pharma market with care, convenience, and cost

g

In today’s challenges, we see the inverse relationship of increasing cost and lower health outcomes through difficulty with access to medications, and a lack of price transparency, education, and communication between Pharma and Providers.


As a digital health service, we believe LitonRx brings these proximities closer to better healthcare through our cost-effective model and concierge service, LitonMD. 


Care: Delivering 24/7 virtual concierge care to patients - digitally keeping pharmacists in touch.


Convenience: Full preauthorization support, with same-day home delivery


Cost: Transparent and affordable monthly subscription and formulary pricing - including a competitor's price match guarantee


Our monthly subscription model for LitonMD is $75 a month (50% margin), and that along with retail sales are the two key sources of revenue.

The Market & Our Traction


In 2020, Pharmacy spending nearly doubled (source)


With that, it makes sense that the market is estimated to grow from $336 billion to potentially $505 Billion by 2023 across developed markets (source). 


Because we focus on the connection between pharmacists, providers, and those seeking care - we feel we have huge market potential with little competition. When it comes to our traction, we have...


  • Opened 4 pharmacy locations 
  • Granted patients access to our provider network to deliver 24/7 virtual care 
  • Expanded licensing to provide pharmacy services to 5 states

And we are anticipating...

  • Nationwide services by Q1 2023
  • Launching LitonMD services Q4 2022

why invest


We believe the LitonRx solution impacts every touchpoint - a potential win for all stakeholders


We believe to be entering a hot space with a growing market and clear digital needs. To us, it is apparent that there is an increase in consumers that are seeking and adopting digital health services for convenience and immediate attention to their needs. In our view, LitonRx is on track for growth and is anticipated to expand in an additional 31 states by the end of the calendar year. 


Overall, our digital technology aims to streamline the prescription process for patients, providers, and payers, making it a win-win for everyone involved. Invest today, and help us build a future of more accessible, transparent digital care.







Bold (⌘B)

ABOUT

HEADQUARTERS
2080 N Dobson Road # 3
Chandler, AZ 85226
WEBSITE
View Site
We believe our healthcare and pharmacy model is broken. Join in our mission to make healthcare and pharmacy affordable and convenient. At LitonRx, we believe in solving this by focusing on the 3 C's of Care, Convenience and Cost through digital enablement. LitonRx offers an affordable digital pharmacy and subscription based concierge virtual care services. Our product, LitonMD, is currently in development and will be coming soon to the market.

TERMS

Liton Rx
Overview
PRICE PER SHARE
$1
DEADLINE
Dec. 23, 2022 at 7:59 AM UTC
VALUATION
$25M
FUNDING GOAL
$10K - $1.24M
Breakdown
MIN INVESTMENT
$500
MAX INVESTMENT
$1,235,000
MIN NUMBER OF SHARES OFFERED
10,000
MAX NUMBER OF SHARES OFFERED
1,235,000
OFFERING TYPE
Equity
SHARES OFFERED
Class A nonvoting commom stocks

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum number of shares offered subject to adjustment for bonus shares. See bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based:

Friends and Family Early Birds

Invest $500 within the first 72 hours and receive 15% bonus shares.

Super Early Bird Bonus

Invest $500 within the first 6 days and receive 10% bonus shares.

Early Bird Bonus

Invest $500 within the first 9 days and receive 5% bonus shares.

Amount-Based:

$5,000+ | Tier 1

Invest $5,000+ and receive access to a private Facebook Group + 1% Bonus Shares.

$10,000+ | Tier 2

Invest $10,000+ and receive access to a private Facebook Group + 2% Bonus Shares.

$25,000+ | Tier 3

Invest $25,000+ and receive access to a private Facebook Group + 5% Bonus Shares.

$50,000+ | Tier 4

Invest $50,000+ and receive access to a private Facebook Group + 10% Bonus Shares.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Liton Rx will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 10 additional shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Any expense labeled “Travel and Entertainment”. Salary payments made to one’s self, a friend or relative.

ALL UPDATES

12.08.22

LitonRx launches LitonMD, a NEW + AFFORDABLE Monthly Healthcare Subscription Plan!

We are thrilled to announce the launch of LitonMD, a NEW + AFFORDABLE monthly healthcare subscription plan that includes:

-Unlimited Virtual Doctor Visits
-Up to 3 Medications for Free
-Same-day Delivery of Prescriptions
-FREE app to schedule visits, refill prescriptions and more!

LitonMD empowers consumers to receive the care they deserve at their fingertips. We want everyone to be a part of our growing community and market disrupting service, so we welcome you to invest now!


12.07.22

Our Newest Location Is Now Open!

Here we grow again! We are excited to announce our newest LitonRx location in Flagstaff, Arizona. We are committed to serving the Flagstaff community with fast, convenient and affordable prescription delivery. With continued growth and new locations on the horizon, we continue to disrupt the digital pharmacy world and providing a hassle-free experience for consumers. 


12.05.22

LitonRX is growing!

Our team is growing! We are pleased to welcome Atul Kumar to the LitonRx team as Chief Development Officer. Atul has 20+ years of experience in market development, managing global client engagements for large-scale projects, programs, products, and P&L operations in the Healthcare, Pharmaceutical, and Life Sciences domain. He has a successful track record of incubating & mentoring global teams, inspiring trust, generating confidence, and developing alliances and collaborative partnerships. In his past roles, Atul has worked with MNCs like GE, Genpact, Infosys, Virtusa, and Infostretch.

10.19.22

Investors Update

We are excited to see our community come in and invest in Liton Rx. Our insiders have invested a total of $10000.00 into the offering to date. We hope you join in as well invest in LITON RX, startengine.com/liton-rx/.


Regards,

Liton Rx Team

10.03.22

120 K Raises in First Week !!

09.28.22

“ Last chance for Super early bird bonus ”

Don’t miss out on the last day to get  10% bonus shares in Liton Rx. Offer expires Thursday, 12 AM. We would love for you to be a part of our community!

Regards,

Team Liton Rx

09.27.22

Liton Rx is offering Early Bird Perks!”

We are offering Perks for a limited amount of time! Invest in Liton Rx within the next 2 days to receive bonus shares.

 

We want everyone to be a part of our community, so invest now to receive bonus shares as a thank you for your early support in our journey.

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign reward.

10%

Stack Venture Club & Rewards!

Members get an extra 10% shares in addition to rewards below!

Venture Club

Venture Club

Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).

$5,000

Tier 1

Invest $5,000+ and receive access to a private Facebook Group + 1% Bonus Shares.

$10,000

Tier 2

Invest $10,000+ and receive access to a private Facebook Group + 2% Bonus Shares.

$25,000

Tier 3

Invest $25,000+ and receive access to a private Facebook Group + 5% Bonus Shares.

$50,000

Tier 4

Invest $50,000+ and receive access to a private Facebook Group + 10% Bonus Shares.

JOIN THE DISCUSSION

0/2500

PINNED BY STARTUP

MB
MANJUNATH BAGEWADI ELLUR

3 years ago

How does Liton Rx work and how it generated revenue? can we have a quick call

1

0

AS
Adam Sampson

3 years ago

With the recent downfall of NowRX, how is your company different and how will it be able to make it through the current economic difficulties? Any big updates on the company?

Show more

0

0

MN
Michael Nadler

3 years ago

How is this any different than truepill or costplusdrugs.com?

1

0

AP
Ashvinkumar Patel

3 years ago

What were the valuations in previous rounds ?

1

0

AP
Ashvinkumar Patel

3 years ago

How many active subscription do you currently have? What is the customer acquisition cost?

Show more

2

0

AP
Ashvinkumar Patel

3 years ago

Is the subscription revenue the main source of income? How can you survive if you provide free consultation and free prescription when doctor’s visit it self cost approx $100 per visit?

Show more

1

0

bT
bryian Tan

3 years ago

What the current revenue?

1

0

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

FAQ Timeline

WHY STARTENGINE?

Rewards Icon
REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

Lock Icon
SECURE

Your info is your info. We take pride in keeping it that way!

Ellipse Icon
DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

FAQS

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$126,161
INVESTORS
17
MIN INVEST
$500
VALUATION
$25M

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary LLC (“SE Primary”), a broker-dealer registered with the SEC and FINRA / SIPC. You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system (ATS) regulated by the SEC and operated by SE Primary. SE Primary is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

StartEngine facilitates three types of primary offerings:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice concerning any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy, or completeness of any information. Neither StartEngine nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors

Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.

StartEngine Secondary (“SE Secondary”) is our investor trading platform. SE Secondary is an SEC-registered Alternative Trading System (“ATS”) operated by SE Primary that matches orders for buyers and sellers of securities. It allows investors to trade shares purchased through Regulation A+, Regulation Crowdfunding, or Regulation D for companies who have engaged StartEngine Secure LLC as their transfer agent. The term “Rapid,” when used in relation to transactions on SE Marketplace, specifically refers to transactions that are facilitated on SE Secondary, This is because, unlike with trades on the StartEngine Bulletin Board (“SE BB”), trades on SE Secondary are executed the moment that they are matched.

StartEngine Bulletin Board (“SE BB”) is a bulletin board platform on which users can indicate to each other their interest to buy or sell shares of private companies that previously executed Reg CF or Reg A offerings not necessarily through SE Primary. As a bulletin board platform, SE BB provides a venue for investors to access information about such private company offerings and connect with potential sellers. All investment opportunities on SE BB are based on indicated interest from sellers and will need to be confirmed. Even if parties express mutual interest to enter into a trade on SE BB, a trade will not immediately result because execution is subject to additional contingencies, including among others, effecting of the transfer of the shares from the potential seller to the potential buyer by the issuer and/or transfer agent. SE BB is distinct and separate from SE Secondary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. By contrast, under SE BB, SE Primary assists with the facilitation of a potential resulting trade off platform including, by among other things, approaching the issuer and other necessary parties in relation to the potential transaction. The term “Extended”, when used in relation to transactions on SE Marketplace denotes that these transactions are conducted via SE BB, and that these transactions may involve longer processing times compared to SE Secondary for the above-stated reasons.

Even if a security is qualified to be displayed on SE Marketplace, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine. It also does not constitute an endorsement, solicitation or recommendation by StartEngine. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, (2) assist in the determination of the fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.